more_reports

California Biopharma Shows Promising Phase 1 Data

Research Report
  ()
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note.

Drug Trial Shows Positive Interim Results for ALS Treatment

  ()
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others.

FDA Decision on Drug for Bone Marrow Due Early 2025

Research Report
  ()
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.

Is This California Biopharma Co. In the Right Place at the Right Time?

Research Report
  ()
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies.

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

  ()
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."

Approval Sought in Japan for New Drug to Lower Cholesterol

Research Report
  ()
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report.

AI Accelerates Breakthroughs in Cancer Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans.

Intratubal Insemination Device Shown Effective, Safe

Research Report
  ()
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report.

Developer of Medical Instruments Attracts Research Coverage

Research Report
  ()
Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report.

Two Firms Aim To Create Functional Cure for Type 1 Diabetes

  ()
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.

Biotech Initiates Phase III Trial for Heart Disease Drug

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.

Breakthrough Therapy Shows Promising Long-Term Results for Depression

  ()
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging."

Analyst Says Biotech's Data Supports Advancement Into Phase III

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.

Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions

  ()
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.

Opportunity Arises for Co. With Cell Pouch

Research Report
  ()
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

  ()
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Regenerative Med Co. Granted Second Tissue License

Research Report
  ()
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report.

New Blood Cancer Treatment Shows Continued Response

Research Report
  ()
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report.

Medical Co. Ready for a Transformative F2025

Research Report
  ()
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.

Revolutionary AI Tools Take Center Stage in Medical Education Symposium

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.

Pharma Stock Has Significant Upside Potential, Analyst Says

Research Report
  ()
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note.